Disc Medicine Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
173
- Stock Symbol
-
IRON
- Investments
-
1
- Share Price
-
$79.95
- (As of Friday Closing)
Disc Medicine General Information
Description
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Contact Information
Website
www.discmedicine.comCorporate Office
- 321 Arsenal Street
- Suite 101
- Watertown, MA 02472
- United States
Corporate Office
- 321 Arsenal Street
- Suite 101
- Watertown, MA 02472
- United States
Disc Medicine Timeline
Disc Medicine Stock Performance
As of 13-Nov-2026, Disc Medicine’s stock price is $79.95. Its current market cap is $3.64B with 45.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $79.95 | $83.23 | $40.00 - $99.50 | $3.64B | 45.5M | 916K | -$6.34 |
Disc Medicine Financials Summary
As of 30-Sep-2026, Disc Medicine has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,856,312 | 2,412,797 | 1,401,065 | 1,025,770 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (265,369) | (235,696) | (129,566) | (91,027) |
| Net Income | (243,102) | (212,184) | (109,357) | (76,429) |
| Total Assets | 699,488 | 806,879 | 496,773 | 367,996 |
| Total Debt | 61,087 | 31,023 | 30,000 | 2,101 |
Disc Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Disc Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Disc Medicine Comparisons
Industry
Financing
Details
Disc Medicine Competitors (8)
One of Disc Medicine’s 8 competitors is Keros Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Keros Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Akebia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Silence Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Rallybio | Formerly VC-backed | New Haven, CT |
Disc Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Disc Medicine Patents
Disc Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231672-A1 | Anti-hemojuvelin antibodies and uses thereof | Pending | 28-Apr-2025 | ||
| US-20260294899-A1 | Methods of treating erythropoietic protoporphyria or x-linked protoporphyria with bitopertin | Pending | 31-Mar-2025 | ||
| WO-2026213234-A1 | Methods of treating erythropoietic protoporphyria or x-linked protoporphyria with bitopertin | Pending | 31-Mar-2025 | ||
| WO-2026117626-A1 | Antibody compositions and uses thereof | Pending | 27-Nov-2024 | ||
| WO-2026117626-A8 | Antibody compositions and uses thereof | Pending | 27-Nov-2024 | C07K16/40 |
Disc Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Disc Medicine Acquisitions (1)
Disc Medicine’s most recent deal was a Merger/Acquisition with Gemini Therapeutics. The deal was made on 28-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Gemini Therapeutics | 28-Dec-2022 | Merger/Acquisition | Drug Discovery |
Disc Medicine ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.2 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Disc Medicine FAQs
-
When was Disc Medicine founded?
Disc Medicine was founded in 2017.
-
Where is Disc Medicine headquartered?
Disc Medicine is headquartered in Watertown, MA.
-
What is the size of Disc Medicine?
Disc Medicine has 173 total employees.
-
What industry is Disc Medicine in?
Disc Medicine’s primary industry is Drug Discovery.
-
Is Disc Medicine a private or public company?
Disc Medicine is a Public company.
-
What is Disc Medicine’s stock symbol?
The ticker symbol for Disc Medicine is IRON.
-
What is the current stock price of Disc Medicine?
As of 13-Nov-2026 the stock price of Disc Medicine is $79.95.
-
What is the current market cap of Disc Medicine?
The current market capitalization of Disc Medicine is $3.64B.
-
Who are Disc Medicine’s competitors?
Keros Therapeutics, Incyte, Akebia Therapeutics, Silence Therapeutics, and Rallybio are some of the 8 competitors of Disc Medicine.
-
What is Disc Medicine’s annual earnings per share (EPS)?
Disc Medicine’s EPS for 12 months was -$6.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
